Loading
MAIA Biotechnology, Inc. Stock: price and insider trades · United States
2 insiders bought €303k of shares over the last 90 days, the latest filed 15 Sept 2026.
MAIA Biotechnology, Inc.: what insiders have been doing
This page follows insider dealings at MAIA Biotechnology, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 20 filings signed by 6 insiders.
Only purchases show up on the open market, 20 purchases in all worth €634k, filed by 6 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Guerrero Ramiro filed the largest purchase, €93k, on 1 September 2026, which represents 0.13% of the company's market value. The buyers include 5 senior executives and 1 chief executive.
With 20 filings in twelve months, the company is more active than the median of 19 filings across the 5,810 companies we follow on the same exchange. Looking back to 2022, when coverage begins, insiders filed 102 purchases and no sales.
The data flag 12 purchases as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 15 September 2026, 33 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
104
Thresholds
n/a
Buy Volume
€4M
102 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleRamiro Guerrero12 buys
Stan Smith12 buys
Vlad Vitoc6 buys
Cristian Luput3 buys
Steven M. Chaouki2 buys
Ngar Yee Louie1 buy
Since the insiders bought
- -18.2%Entry US$1.37 · Close 15 Oct 2026 US$1.12
- -2.7%Entry US$1.48 · Close at T+90 US$1.44
- -2.7%Entry US$1.48 · Close at T+90 US$1.44
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate MAIA Biotechnology, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$12.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.16
Analyst consensus
2 analystsStrong buy
US$10.00Target US$12.00(+934%)US$14.00
Income statement
EBITDA-US$22.4M
Net income-US$22.4M0.0% margin
Valuation
PER (forward)1.0x
P/Book3.4x
Beta0.28
Balance sheet & cash
Market capUS$71.6M
Free Cash Flow-US$18.8M
Profitability & ownership
ROE-218.7%
ROA-92.1%
% insiders14.4%
% institutions21.9%
Last declaration on 15 September 2026
Declarations104 total
73,000 shares@ US$1.370.12% mcap37.5% of flowCommon StockSEC:0001878313-26-000087:0
Canonical exit: 13 Dec 2026 (T+90)
37,595 shares@ US$1.31710.060% mcap5.3% of flowCommon StockSEC:0001878313-26-000084:0
Canonical exit: 9 Dec 2026 (T+90)
8,931 shares@ US$1.390.015% mcap1.3% of flowCommon StockSEC:0001878313-26-000082:0
Canonical exit: 24 Nov 2026 (T+90)
78,239 shares@ US$1.390.13% mcap11.5% of flowCommon StockSEC:0001878313-26-000082:1
Canonical exit: 25 Nov 2026 (T+90)
46,620 shares@ US$1.350.077% mcap6.7% of flowCommon StockSEC:0001878313-26-000082:2
Canonical exit: 26 Nov 2026 (T+90)
1,794 shares@ US$1.330.0029% mcap0.3% of flowCommon StockSEC:0001878313-26-000079:0
Canonical exit: 22 Nov 2026 (T+90)
11,899 shares@ US$1.370.020% mcap1.7% of flowCommon StockSEC:0001878313-26-000077:0
Canonical exit: 18 Nov 2026 (T+90)
2,700 shares@ US$3.68840.4% of flowCommon StockSEC:0001878313-26-000021:0
Canonical exit: 18 Dec 2022 (T+90)
57,189 shares@ US$1.2242.4% of flowCommon StockSEC:0001878313-25-000073:0
Canonical exit: 22 Mar 2026 (T+90)
40,849 shares@ US$1.22427.5% of flowCommon StockSEC:0001878313-25-000071:0
Canonical exit: 22 Mar 2026 (T+90)
81,699 shares@ US$1.22417.1% of flowCommon StockSEC:0001878313-25-000069:0
Canonical exit: 22 Mar 2026 (T+90)
4,580 shares@ US$1.19970.2% of flowCommon StockSEC:0001878313-25-000063:0
Canonical exit: 5 Mar 2026 (T+90)
22,000 shares@ US$1.04630.026% mcap8.6% of flowCommon StockSEC:0001878313-25-000059:0
Canonical exit: 24 Feb 2026 (T+90)
50,000 shares@ US$1.136621.3% of flowCommon StockSEC:0001878313-25-000056:0
Canonical exit: 26 Feb 2026 (T+90)
20,000 shares@ US$1.08089.5% of flowCommon StockSEC:0001878313-25-000054:0
Canonical exit: 24 Feb 2026 (T+90)
15,000 shares@ US$1.03880.6% of flowCommon StockSEC:0001878313-25-000052:0
Canonical exit: 24 Feb 2026 (T+90)
10,000 shares@ US$0.97854.3% of flowCommon StockSEC:0001878313-25-000050:0
Canonical exit: 23 Feb 2026 (T+90)
10,500 shares@ US$0.96613.8% of flowCommon StockSEC:0001878313-25-000047:0
Canonical exit: 23 Feb 2026 (T+90)
10,000 shares@ US$0.990.4% of flowCommon StockSEC:0001878313-25-000045:0
Canonical exit: 22 Feb 2026 (T+90)
1,800 shares@ US$0.920.6% of flowCommon StockSEC:0001878313-25-000040:0
Canonical exit: 19 Feb 2026 (T+90)
19,230 shares@ US$1.300.9% of flowCommon StockSEC:0001878313-25-000019:0
Canonical exit: 30 Dec 2025 (T+90)
33,333 shares@ US$1.501.8% of flowCommon StockSEC:0001127602-25-016869:0
Canonical exit: 1 Sept 2025 (T+90)
20,000 shares@ US$1.503.3% of flowCommon StockSEC:0001127602-25-013965:0
Canonical exit: 6 Aug 2025 (T+90)
66,666 shares@ US$1.503.6% of flowCommon StockSEC:0001127602-25-013963:0
Canonical exit: 6 Aug 2025 (T+90)
25,000 shares@ US$1.501.5% of flowCommon StockSEC:0001127602-25-008327:0
Canonical exit: 1 Jun 2025 (T+90)
25 of 104 declarations
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a U.S.-based clinical-stage biopharmaceutical company listed on NYSE American (NYSE) in the United States. Founded in 2018 and incorporated in Delaware in August 2018, the company is headquartered in Chicago, Illinois, with a distributed team that also operates remotely from other U.S. locations and selected international sites. MAIA is not yet a commercial-stage business; it remains a research-driven oncology developer, which means its investment profile is that of a capital-intensive small-cap biotech with binary clinical and financing milestones.
The company’s core activity is the development of targeted cancer therapies, led by its flagship investigational asset ateganosine, also referred to as THIO or 6-thio-dG. Ateganosine is a first-in-class telomere-targeting agent designed to attack telomerase-active cancer cells and to be used in sequence with immune checkpoint inhibitors. MAIA is primarily focused on non-small cell lung cancer (NSCLC), especially late-line settings where patients have failed prior standard therapies. This positions the company in a highly competitive but scientifically differentiated segment of immuno-oncology. Its value proposition is based on a niche mechanism of action rather than broad platform diversification.
Read moreShow less
From a clinical development perspective, MAIA has advanced its lead program through multiple key stages. The company obtained U.S. IND clearance for THIO-101, selected a development dose in Phase 2, and initiated the pivotal Phase 3 program THIO-104 in 2025. In 2026, management stated that recent financing proceeds are expected to fully fund the ongoing pivotal trial. MAIA also activated its first U.S. site for the expansion of THIO-101, adding to an already international clinical footprint that has included Europe and Australia. Additional corporate developments have included a clinical supply agreement with Roche and repeated equity financings, underscoring the company’s reliance on external capital to execute its pipeline.
Recent news flow has been dominated by clinical progress and financing rather than commercial execution. MAIA announced a March 2026 underwritten public offering and later indicated that the proceeds, combined with prior capital raising, should support the Phase 3 program. The company has also continued to highlight its telomere-targeting differentiation and early efficacy signals in NSCLC. For investors, the main opportunity lies in the potential clinical validation of a novel oncology mechanism; the main risks remain execution, dilution, regulatory uncertainty, and the lack of revenue. In short, MAIA is a high-risk, high-upside U.S. listed biotech story on NYSE American, with valuation driven almost entirely by clinical data readouts and funding visibility.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
